FDORA Accelerated Approval Reform

Accelerated Approval was codified in 1992 (Subpart H for drugs, Subpart E for biologics) to let FDA approve products for serious conditions on the basis of a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required post-approval to verify and describe clinical benefit. The pathway accelerated access to important medicines but accumulated criticism over three issues:

• Confirmatory trials sometimes started years after approval and ran for years more, leaving products on the market for a decade or longer without verified benefit.
• Withdrawal of approval for products that failed confirmatory trials was slow and contested (Makena, Aduhelm, accelerated-approval cancer drugs).
• Sponsors had limited transparency obligations on confirmatory-trial progress; OIG and GAO reports flagged systemic enforcement gaps.

FDORA addresses each of these directly.

• FDA may require confirmatory trials to be underway at the time of accelerated approval (not just specified post-approval).
• FDA may specify the conditions of confirmatory trials at the time of accelerated approval, including study design, target population, milestones and timelines.
• Sponsors must submit reports on confirmatory-trial progress every six months until the studies are completed.
• FDA may use expedited withdrawal procedures if a sponsor fails to conduct any required post-approval study with due diligence, fails to submit timely reports, disseminates false or misleading promotional material, or if the confirmatory trial fails to verify clinical benefit.
• FDA may establish an internal coordinating council to ensure consistent and appropriate use of AA across centers.
• Public disclosure of post-marketing study commitments and their status is strengthened.

Pre-FDORA, withdrawal of an AA approval typically required protracted administrative proceedings, including advisory committee meetings and formal hearings (the Makena process took ~16 months from FDA's recommendation to formal withdrawal). FDORA authorises FDA to use procedures 'no less protective of consumer interests' than the traditional process but more streamlined, including:

• Due notice to the sponsor with opportunity to request a meeting and submit written argument.
• Advisory committee consultation where FDA determines appropriate.
• Final agency action on a defined timeline rather than open-ended.
• Judicial review available under the APA, but on the expedited record.

Every six months until the confirmatory trial is complete, the sponsor must submit a progress report covering enrolment, timeline adherence, protocol modifications, interim data (where applicable), and any anticipated delays. Reports are filed under the existing post-marketing requirements/commitments (PMR/PMC) framework but with formalised content expectations and disclosure consequences.

FDA's December 2024 draft guidance 'Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics' integrates FDORA into the existing AA framework. The guidance:

• Reaffirms surrogate-endpoint expectations and the standard 'reasonably likely to predict clinical benefit'.
• Articulates when FDA expects confirmatory trials to be underway at approval (typically when the trial is feasible to start pre-approval and where delays would compromise confirmation).
• Sets out the six-month report content expectations.
• Describes the expedited withdrawal procedural framework.
• Reiterates the AA-specific promotional review and labelling expectations.
• Addresses real-world evidence and external control arms as components of confirmatory packages where randomised trials are not feasible.

1. Confirmatory-trial readiness is now a pre-approval lever, not a post-approval task. Start confirmatory enrolment early enough that FDA can find it 'underway' at approval.
2. Six-month reporting demands a sustained internal cadence with clinical, statistical, regulatory and PV teams aligned around milestone reporting.
3. Public disclosure of progress means commercial and IR teams must be ready for stakeholder questions about confirmatory data — not just at primary readout but every six months.
4. Withdrawal-risk premium changes the economics of AA pipeline assets. Modelling should reflect faster, more credible withdrawal scenarios than pre-FDORA.
5. Real-world evidence and external-control approaches become more attractive where they accelerate or de-risk confirmation, but the evidentiary bar for the primary endpoint remains substantial.

FDA's use of the expedited withdrawal procedure was tested in 2023 with the Makena withdrawal (completed under transitional procedures) and observed across oncology AA withdrawals through 2024. The pattern is clear: FDA expects confirmatory commitments to be honoured on time, and sponsors that allow drift face faster regulatory action than they would have a decade earlier.